Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors

Trial Profile

Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs DS 5573a (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 24 Feb 2017 Status changed from recruiting to discontinued.
    • 18 Feb 2016 Dose level 1.5 added in the treatment table, so total dose levels changed from 7 to 8, according to ClinicalTrials.gov record.
    • 18 Feb 2016 Planned number of patients changed from 51 to 57, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top